Clinical Trial Search

Primary: Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12 — -0.21; -0.21 nanomoles per…

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit — 0.834; 0.775 nmol/L — p=0.048

Primary: Change in Hemoglobin A1c — 2.67; 1.05 percentage change from baseline

Primary: Number of All Consented Participants — 12; 12 Participants

Primary: Insulin Sensitivity — 0.1; 0.07 mL/kg/min per uU/mL

Primary: Residual Beta-cell Function (RBCF) — 1.78; 2.27; 1.56; 1.76 ng/ml — p=<0.001

Primary: Change in GAD65 Autoantibody Titer (DK Units/mL) — 247; 234; 193; 196 DK Units/mL

Primary: Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12 — -0.14; -0.23 nanomoles per…

Primary: Insulin Sensitivity — 8.6; 6.2; 5.8; 4.8 mg/kg/min

Primary: Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year — 71 Percentage of patients

Primary: Adverse Events — 2; 2 Serious adverse events

Primary: The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation — 5 participants

Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Primary: Number of Participants With Type 1 Diabetes Mellitus — 82; 91 participants

Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL

Primary: Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months — -5.20; -4.83 nmol*min/L — p=0.33

Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL

Primary: Glucose Levels Percent Time in Target Range Based on Glucose Monitoring — 61.185; 64.542; 62.223; 64.571 percentage of time-in-range — p=0.777

Primary: Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation. — 44; 14; 17; 14…

Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year — 0.58; 0.429 pmol per mL — p=0.05

Primary: Change in Insulin Sensitivity Assessed as Glucose Infusion Rates — 8.6; 8.1 mg/kg FFM/min — p=<0.01

Primary: Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months — -3.848; -4.348 nmol*minute/L — p=0.2851

Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL

Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87

Primary: Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B…

Primary: Glucose Control as Assessed by Mean Glucose Levels